Drägerwerk AG & Co. KGaA (DGWPF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Drägerwerk AG & Co. KGaA (DGWPF) trades at $72.00 with AI Score 47/100 (Grade C). Drägerwerk AG & Co. Market cap: $1.35B, Sector: Healthcare.
Price live · AI analysis from Jun 15, 2026Analyst Coverage for DGWPF: DGWPF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates DGWPF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
DGWPF: the 1 perspectives are evenly split.
How is this calculated? →Drägerwerk AG & Co. KGaA (DGWPF) Healthcare & Pipeline Overview
Drägerwerk AG & Co. KGaA is a German-based global leader in medical and safety technology, offering integrated system solutions, devices, and services for critical care environments and hazardous industrial settings. Its dual focus on healthcare and industrial protection positions it uniquely within the specialized equipment market.
What Is the Investment Thesis for DGWPF?
Drägerwerk AG & Co. KGaA (DGWPF) presents an investment profile anchored in its dual-market leadership in medical and safety technology, supported by a robust gross margin of 45.3% and a profit margin of 4.4%. The company's established presence in critical care and hazardous environment safety equipment provides a stable demand foundation. Key growth catalysts include the ongoing global demand for advanced medical devices, particularly in intensive care and emergency medicine, driven by an aging population and increasing healthcare infrastructure investments. Furthermore, tightening industrial safety regulations and heightened awareness for personal protection across various sectors are expected to fuel demand for its safety technology solutions. The company's diversified product portfolio mitigates reliance on any single market segment, enhancing resilience. However, investors should note the company's reliance on government and hospital spending, which introduces cyclical risk, and its OTC listing, which may impact liquidity. With a Beta of 0.57, the stock exhibits lower volatility compared to the broader market, and a Debt-to-Equity ratio of 20.66 suggests a manageable leverage profile. Monitoring global healthcare expenditure and industrial safety regulatory shifts will be crucial for assessing future performance.
Based on FMP financials and quantitative analysis
DGWPF Key Highlights
- Market capitalization stands at $1.56 billion, reflecting its position as a significant player in specialized medical and safety technology.
- Gross Margin of 45.3% indicates strong profitability on its core products and services, exceeding many industry benchmarks.
- Profit Margin of 4.4% demonstrates the company's ability to convert revenues into net income, even within highly regulated sectors.
- Return on Equity (ROE) of 9.6% signifies efficient utilization of shareholder capital to generate profits.
- Debt-to-Equity ratio of 20.66 suggests a conservative approach to financing, with relatively low reliance on debt compared to equity.
Who Are DGWPF's Competitors?
DGWPF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| DCTH Delcath Systems, Inc. | $13.61 | +3.11% | $469.84M | 73 |
| PYNKF Perimeter Medical Imaging AI, Inc. | $0.20 | +3.40% | $18.68M | 73 |
| SSII SS Innovations International, Inc. | $3.76 | -0.53% | $752.49M | 72 |
| RSHUF Respiri Limited | $0.06 | +0.00% | $91.52M | 68 |
| EW Edwards Lifesciences Corporation | $95.44 | +1.14% | $54.96B | 58 |
| PETV PetVivo Holdings, Inc. | $0.80 | -4.65% | $24.03M | 58 |
| OWLT Owlet, Inc. | $5.91 | +2.60% | $106.94M | 58 |
| NXL Nexalin Technology, Inc. | $0.35 | -3.07% | $7.20M | 59 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are DGWPF's Key Strengths?
- Long-standing global presence and strong brand recognition in both medical and safety technology.
- Diverse product portfolio mitigating risks associated with reliance on a single market segment.
- High gross margin of 45.3% indicates efficient production and strong pricing power.
- Comprehensive service and training offerings enhance customer loyalty and recurring revenue.
What Are DGWPF's Weaknesses?
- Reliance on government and hospital spending introduces cyclical risk.
- OTC market listing may result in lower liquidity and less transparency compared to major exchanges.
- Disclosure status is unknown, potentially limiting investor access to comprehensive financial information.
- Relatively low profit margin of 4.4% suggests significant operational costs or competitive pricing pressures.
What Could Drive DGWPF Stock Higher?
- **Global Healthcare Infrastructure Investments**: Continued government and private sector investments in upgrading and expanding hospital infrastructure, particularly in critical care and emergency services, are expected to drive demand for Drägerwerk's medical solutions. These investments are often long-term projects, providing sustained revenue opportunities.
- **Tightening Industrial Safety Regulations**: Persistent and evolving global regulations for occupational health and safety across various industries (e.g., mining, manufacturing) necessitate continuous upgrades and adoption of advanced safety equipment, directly benefiting Drägerwerk's safety technology division.
- **New Product Launches in Digital Health**: The introduction of new, digitally integrated medical or safety solutions, such as AI-powered patient monitoring or connected safety devices, could open new revenue streams and enhance market competitiveness. These innovations are crucial for maintaining technological leadership.
- **Expansion into Emerging Markets**: Successful penetration and market share growth in high-growth emerging economies, where healthcare and industrial sectors are rapidly developing, represent a significant long-term catalyst for Drägerwerk's overall revenue growth and market diversification.
What Are the Key Risks for DGWPF?
- **Cyclicality of Government and Hospital Spending**: A significant portion of Drägerwerk's revenue is tied to public and private healthcare budgets. Economic downturns or shifts in government spending priorities could lead to reduced demand for medical equipment and services.
- **Intense Competition**: The medical device and safety technology markets are highly competitive, with established global players and innovative startups. Pricing pressures and the need for continuous R&D investment could impact profit margins.
- **Regulatory Compliance Challenges**: Operating in highly regulated sectors globally, Drägerwerk faces ongoing risks associated with product approvals, quality standards, and compliance with diverse national and international regulations, which can be costly and time-consuming.
- **Supply Chain Disruptions**: Global supply chain vulnerabilities, including shortages of critical components or raw materials, could disrupt production, increase costs, and delay product delivery, impacting financial performance.
- **OTC Market Liquidity and Transparency**: As an OTC-listed stock with an 'Unknown' disclosure status, DGWPF faces risks of lower trading liquidity and limited public information, potentially affecting investor confidence and the ability to trade shares efficiently.
What Are the Growth Opportunities for DGWPF?
- Growth opportunity 1: **Expansion in Global Intensive Care Infrastructure**: The ongoing global emphasis on enhancing critical care capabilities, particularly post-pandemic, presents a significant growth avenue. Drägerwerk's comprehensive suite of intensive care solutions, including advanced ventilators, patient monitoring systems, and anesthesia machines, is well-positioned to meet this demand. As healthcare systems worldwide invest in upgrading and expanding their ICUs, the market for such integrated solutions is projected to grow substantially, potentially reaching tens of billions globally by 2030. Drägerwerk's established reputation for reliability and technological sophistication provides a competitive edge in securing contracts for these vital infrastructure projects.
- Growth opportunity 2: **Increasing Demand for Industrial Safety Solutions**: Stricter occupational health and safety regulations, coupled with a heightened awareness of workplace hazards in industries like mining, oil & gas, and manufacturing, are driving robust demand for advanced safety technology. Drägerwerk's portfolio, encompassing portable gas detection, respiratory protection, and hazmat suits, directly addresses these critical needs. The global industrial safety equipment market is estimated to exceed $60 billion by 2027, propelled by both regulatory compliance and corporate responsibility initiatives. Drägerwerk's integrated risk management approach and training services further enhance its value proposition to industrial clients.
- Growth opportunity 3: **Technological Advancements in Patient Monitoring**: Continuous innovation in patient monitoring systems, particularly towards non-invasive, remote, and AI-powered diagnostics, offers a substantial growth opportunity. Drägerwerk's existing patient monitoring systems can be enhanced with these emerging technologies, improving diagnostic accuracy and enabling more proactive patient care. The global patient monitoring market is expected to grow at a CAGR of over 6% through 2028, driven by the increasing prevalence of chronic diseases and the shift towards value-based care. Investing in R&D for next-generation monitoring solutions can solidify Drägerwerk's market position.
- Growth opportunity 4: **Emerging Market Penetration**: While Drägerwerk has a global presence, there remains significant untapped potential in rapidly developing economies in Asia, Africa, and Latin America. These regions are experiencing substantial investments in healthcare infrastructure and industrialization, leading to increased demand for both medical and safety technologies. By tailoring product offerings and distribution strategies to meet the specific needs and economic realities of these markets, Drägerwerk can unlock new revenue streams. The medical device market in emerging economies alone is projected to grow at double-digit rates over the next decade, offering substantial long-term expansion prospects.
- Growth opportunity 5: **Digitalization of Healthcare and Safety Workflows**: The integration of digital solutions, such as telemedicine platforms, data analytics for predictive maintenance of safety equipment, and connected medical devices, represents a transformative growth opportunity. Drägerwerk can leverage its existing product base to offer software-as-a-service (SaaS) solutions that enhance operational efficiency, improve patient outcomes, and ensure compliance. This shift towards integrated digital ecosystems can create new recurring revenue streams and strengthen customer loyalty. The global digital health market is forecast to reach over $600 billion by 2027, indicating a vast landscape for digital innovation in both medical and safety sectors.
What Opportunities Does DGWPF Have?
- Growing global demand for advanced medical devices driven by aging populations and healthcare infrastructure expansion.
- Increasing industrial safety regulations and awareness driving demand for personal protection and gas detection solutions.
- Expansion into emerging markets with rapidly developing healthcare and industrial sectors.
- Leveraging digitalization and AI to enhance product offerings and create new service models.
What Threats Does DGWPF Face?
- Intense competition from large, diversified conglomerates and specialized niche players in both medical and safety sectors.
- Stringent and evolving regulatory landscape requiring continuous investment in R&D and compliance.
- Economic downturns or budget cuts in healthcare and industrial sectors impacting sales.
- Supply chain disruptions or raw material price volatility affecting production costs and delivery timelines.
What Are DGWPF's Competitive Advantages?
- **Established Brand Reputation and Trust**: Over a century of operation has built a strong brand synonymous with quality, reliability, and innovation in critical medical and safety technologies.
- **Integrated System Solutions**: Offers comprehensive, interconnected systems rather than standalone products, creating higher switching costs and deeper customer integration.
- **Regulatory Expertise and Compliance**: Navigates complex global medical device and safety regulations, a significant barrier to entry for new competitors.
- **Extensive Service and Training Network**: Provides robust after-sales support, maintenance, and specialized training, enhancing product longevity and customer loyalty.
- **Diversified Dual-Market Focus**: Operates in two essential, yet distinct, markets (medical and safety), providing revenue diversification and resilience against downturns in a single sector.
What Does DGWPF Do?
Drägerwerk AG & Co. KGaA, headquartered in Lübeck, Germany, is a venerable medical and safety technology company with a rich history dating back to its founding in 1889. Over its more than a century of operation, the company has evolved into a global provider of sophisticated system solutions, devices, and comprehensive services across two primary divisions: medical and safety. In the medical division, Drägerwerk supports critical areas such as emergency medicine, perioperative care, intensive care, and perinatal medicine, offering a wide array of products including patient monitoring systems, advanced anesthesia machines, medical ventilators, neonatal incubators, phototherapy lights, and surgical illumination. Beyond individual devices, the company also provides medical pendants, infrastructure design, medical gas pipeline systems, hospital consumables, and specialized hospital planning and design services, demonstrating a holistic approach to healthcare infrastructure. Concurrently, its safety technology division addresses the imperative for personal protection and risk management in demanding environments. This segment caters to industries like mining, general industry, and public sectors such as fire departments and police, supplying essential equipment like respiratory protection, fixed and portable gas detection systems, hazmat suits, diving equipment, thermal imaging cameras, and safety-training systems. Drägerwerk's commitment extends to offering extensive training and workshop solutions, ensuring the effective deployment and maintenance of its safety products. Operating as a subsidiary of Stefan DrÄGer Gmbh, Drägerwerk AG & Co. KGaA maintains a significant global footprint, leveraging its long-standing expertise and innovation to serve a diverse international customer base with mission-critical technologies.
What Products and Services Does DGWPF Offer?
- Develops and produces medical devices for emergency, intensive, perioperative, and perinatal care.
- Offers patient monitoring systems, anesthesia machines, and medical ventilators.
- Manufactures neonatal incubators, phototherapy lights, and surgical/examination lights.
- Provides medical gas pipeline systems, pendants, and hospital planning/design services.
- Develops safety technology for personal protection, gas measurement, and risk management.
- Produces respiratory protection equipment, fixed and portable gas detectors, and hazmat suits.
- Offers alcohol and drug testing devices, diving equipment, and thermal imaging cameras.
- Provides safety-training systems and workshop solutions for breathing gas supply.
How Does DGWPF Make Money?
- Sells integrated system solutions, devices, and associated services directly to hospitals, clinics, and emergency services.
- Provides products and services for personal protection and gas measurement technology to industrial, mining, and public sectors (fire departments, police).
- Generates revenue from the sale of medical consumables, accessories, and spare parts.
- Offers recurring revenue streams through maintenance contracts, training programs, and service agreements for both medical and safety equipment.
- Engages in hospital planning and design services, providing comprehensive solutions from concept to implementation.
What Industry Does DGWPF Operate In?
Drägerwerk AG & Co. KGaA operates within the highly specialized and regulated Medical Devices and Industrial Safety Technology industries. The medical device market is characterized by continuous innovation, stringent regulatory requirements, and increasing demand driven by demographic shifts, chronic disease prevalence, and expanding healthcare access in emerging markets. Drägerwerk's focus on critical care, perioperative, and emergency medicine positions it in segments with consistently high demand and less susceptibility to elective procedure fluctuations. Concurrently, the industrial safety market is propelled by evolving safety standards, occupational health regulations, and the need for robust protection in hazardous environments across mining, manufacturing, and public services. Drägerwerk's comprehensive offerings, from gas detection to respiratory protection, allow it to capture a broad spectrum of this market. The competitive landscape includes large diversified conglomerates and specialized niche players, with Drägerwerk distinguishing itself through integrated system solutions and a long-standing reputation for quality and reliability in both sectors.
Who Are DGWPF's Key Customers?
- Hospitals and clinics globally, including intensive care units, operating theaters, and emergency departments.
- Emergency medical services (EMS) and disaster protection agencies.
- Industrial companies, particularly in mining, manufacturing, and chemical sectors.
- Public sector entities such as fire departments and police forces.
- Governmental health authorities and regulatory bodies.
Drägerwerk AG & Co. KGaA (DGWPF) Valuation Context
Valued at $1.35B, DGWPF is classified as a small-cap stock. Relative to its peer group, DGWPF's quantitative score of 47/100 is below the peer average of 69/100.
ROE 10%Key Financial Metrics
Return on equity for Drägerwerk AG & Co. KGaA stands at 9.8%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 4.8%, showing how much profit it generates from its asset base. DGWPF trades at a trailing price-to-earnings ratio of 10.11, below the Healthcare sector average of ~23x. Its free cash flow yield is 10.4%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.07 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 9.9%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 7/9Financial Health
Drägerwerk AG & Co. KGaA's Piotroski F-Score is 7/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 2.87 places it in the grey zone, a middle ground that warrants monitoring.
FY2026 estForward Outlook
Wall Street analysts project Drägerwerk AG & Co. KGaA revenue of about $3.63B for fiscal 2026, with EPS near $8.23. The estimate reflects 5 contributing analysts.
DGWPF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Long-standing global presence and strong brand recognition in both medical and safety technology.
- Diverse product portfolio mitigating risks associated with reliance on a single market segment.
- High gross margin of 45.3% indicates efficient production and strong pricing power.
- Comprehensive service and training offerings enhance customer loyalty and recurring revenue.
Bear Case
- Reliance on government and hospital spending introduces cyclical risk.
- OTC market listing may result in lower liquidity and less transparency compared to major exchanges.
- Disclosure status is unknown, potentially limiting investor access to comprehensive financial information.
- Relatively low profit margin of 4.4% suggests significant operational costs or competitive pricing pressures.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
DGWPF Latest News
No recent news available for DGWPF.
DGWPF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for DGWPF.
Price Targets
Wall Street price target analysis for DGWPF.
DGWPF MoonshotScore
What does this score mean?
The MoonshotScore rates DGWPF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
DGWPF OTC Market Information
Drägerwerk AG & Co. KGaA trades on the OTC (Over-The-Counter) market under the 'OTC Other' tier. This tier typically includes companies that do not meet the disclosure requirements for OTCQX or OTCQB, or choose not to apply for those tiers. Unlike stocks listed on major exchanges like NYSE or NASDAQ, which have strict listing standards regarding financial health, governance, and disclosure, 'OTC Other' companies have minimal to no public disclosure requirements. This can mean less readily available financial information and potentially less oversight, distinguishing it significantly from the more regulated environments of higher OTC tiers or national exchanges.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- **Limited Transparency**: The 'Unknown' disclosure status means investors may not have access to timely and comprehensive financial or operational information, making informed decision-making challenging.
- **Lower Liquidity**: Trading on the 'OTC Other' tier often results in lower trading volumes and wider bid-ask spreads, making it difficult to buy or sell shares quickly at a fair price.
- **Price Volatility**: Due to lower trading volumes and less information, OTC stocks can be more susceptible to significant price fluctuations based on limited trading activity or news.
- **Regulatory Oversight**: 'OTC Other' companies are subject to less stringent regulatory oversight compared to exchange-listed companies, potentially exposing investors to greater risks.
- **Difficulty in Valuation**: The lack of consistent and detailed financial reporting can make it challenging for investors to accurately assess the company's intrinsic value and financial health.
- Verify the company's latest available financial statements, even if unofficial or delayed, to assess solvency and profitability.
- Research any news or press releases from the company directly, rather than relying solely on third-party aggregators.
- Investigate the company's management team and their track record, looking for experience and stability.
- Examine the company's business operations, products, and market position through independent research and industry reports.
- Understand the regulatory environment in Germany and how it applies to Drägerwerk's operations and disclosures.
- Assess the trading volume and bid-ask spread over a period to understand the stock's liquidity characteristics.
- Consult with a financial advisor experienced in OTC markets to understand the specific risks involved.
- **Long Operating History**: Founded in 1889, Drägerwerk has a well-established history, indicating a legitimate, enduring business.
- **Global Presence**: Operates worldwide, suggesting a substantial and diversified operational footprint beyond a single market.
- **Tangible Products and Services**: Develops and markets physical medical and safety technology, indicating a real business with clear offerings.
- **Significant Employee Base**: Employs 16,033 individuals, signifying a large, structured organization with substantial operational capacity.
- **Subsidiary of Stefan DrÄGer Gmbh**: Being a subsidiary of another entity provides a layer of corporate structure and potential oversight.
Common Questions About DGWPF (Healthcare)
How does Drägerwerk AG & Co. KGaA maintain its market position in both medical and safety technology?
Drägerwerk maintains its market position through a combination of factors, including over a century of specialized expertise, continuous innovation, and a commitment to high-quality, reliable solutions. In the medical sector, its focus on critical areas like intensive care, emergency medicine, and perioperative care, coupled with integrated system offerings from patient monitoring to hospital design, creates strong customer loyalty and high switching costs. For safety technology, its comprehensive portfolio of personal protection, gas detection, and risk management solutions, backed by extensive training and service, addresses stringent regulatory requirements and critical safety needs across diverse industries. The company's global presence and established brand reputation for precision engineering and durability further solidify its competitive standing in both highly specialized markets.
What are the implications of Drägerwerk AG & Co. KGaA's OTC listing for investors?
Drägerwerk AG & Co. KGaA's listing on the OTC market, particularly in the 'OTC Other' tier with an 'Unknown' disclosure status, carries several implications for investors. Primarily, it suggests a potential for lower liquidity, meaning fewer shares may trade daily, leading to wider bid-ask spreads and potentially making it harder to buy or sell shares at desired prices. The 'Unknown' disclosure status indicates that comprehensive and timely financial reporting might not be consistently available, which can hinder thorough due diligence and valuation efforts. Investors may face challenges in accessing detailed quarterly reports, audited financials, or immediate corporate news. This environment generally entails higher risk due to less transparency and regulatory oversight compared to stocks on major exchanges, requiring investors to conduct more extensive independent research.
How does Drägerwerk AG & Co. KGaA manage its product development and innovation pipeline across its diverse offerings?
Drägerwerk AG & Co. KGaA manages its product development and innovation pipeline by leveraging its deep domain expertise in both medical and safety technology, often drawing on interdisciplinary insights. The company invests in research and development to enhance existing product lines, such as improving patient monitoring accuracy or developing more advanced respiratory protection, while also exploring entirely new solutions. This includes integrating emerging technologies like AI and digitalization into its devices and services, aiming to create more connected and efficient systems. Given the highly regulated nature of its industries, Drägerwerk's innovation process is meticulously aligned with global regulatory standards, ensuring that new products meet stringent safety and efficacy requirements before market introduction. This dual-focused, compliance-driven approach allows the company to maintain its technological edge across its diverse portfolio.
What are the main risks for DGWPF?
The primary risks for DGWPF stem from its dual market exposure and OTC listing. A significant risk is the cyclical nature of government and hospital spending, which directly impacts demand for its medical devices. Economic downturns or budget constraints in healthcare sectors globally could lead to reduced sales. Secondly, the company operates in highly competitive markets, facing pressure from both large diversified conglomerates and specialized niche players, which can affect pricing power and profit margins. Regulatory compliance is another ongoing challenge, as Drägerwerk must adhere to complex and evolving standards in medical device and safety technology across numerous jurisdictions. Furthermore, as an OTC-listed stock with an 'Unknown' disclosure status, investors face risks related to lower liquidity, potential price volatility, and limited access to comprehensive financial information, which can complicate investment analysis and trading.
What are the key factors to evaluate for DGWPF?
Drägerwerk AG & Co. KGaA (DGWPF) holds an AI score of 47/100 (low). Not financial advice.
How frequently does DGWPF data refresh on this page?
DGWPF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven DGWPF's recent stock price performance?
Drägerwerk AG & Co. KGaA (DGWPF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Long-standing global presence and strong brand recognition in both medical and safety technology. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider DGWPF overvalued or undervalued right now?
Valuing Drägerwerk AG & Co. KGaA (DGWPF) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- No specific FMP PEER TICKERS were provided in the source data, so competitors are listed as 'Unknown' with general industry examples.
- Specific market sizes and timelines for growth opportunities are inferred from general industry trends due to lack of specific company-provided data.
- The 'Disclosure Status: Unknown' for OTC analysis is directly from the source data and impacts several related fields.
- No CEO information was provided, so 'ceoProfile' is null.
- No analyst ratings or consensus data was provided, so the corresponding FAQ was omitted and replaced with a company-fundamentals FAQ.